EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advances in immune checkpoint inhibitors therapy for small cell lung cancer

Longhui Li iD, Yangyueying Liang, Minghui Yu, Lu Zhao, Qingyun Mei, Yongchao Yu, Na Wang iD, Dou Zhang, Ziwei Wang, Yingjie Jia, Fanming Kong

Cancer Medicine · 2023-05 · 12 (10) · 11097-11106

DOI: 10.1002/cam4.5659 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Medicine, online erschienen am 07.03.2023. Verfasst von Longhui Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

As one of the most aggressive neuroendocrine tumors, small cell lung cancer (SCLC) has the most disappointing prognosis of all lung cancers. Although SCLC responds well to initial chemotherapy, the majority of patients experience disease recurrence within one year, and patient survival is poor. It is still necessary to explore the application of ICIs in SCLC since the beginning of the road to immunotherapy, which broke the 30‐year treatment deadlock of SCLC.

Methods

We searched PubMed, Web of Science, and Embase with search terms such as "SCLC", "ES‐SCLC", "ICIs", and "ICBs", and categorized and summarized the relevant literature obtained, and we compiled the latest progress about the application of ICIs in SCLC.

Results

We listed 14 clinical trials on ICIs, including 8 clinical trials on first‐line SCLC treatment, 2 clinical trials on second‐line SCLC treatment, 3 clinical trials on third‐line SCLC treatment, and 1 clinical trial on SCLC maintenance treatment.

Conclusion

ICIs in combination with chemotherapy can improve OS in SCLC patients, but the extent to which SCLC patients can benefit from ICIs is limited, and ICIs' combination treatment strategies still need to be continuously explored.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaLung NeoplasmsHumansImmune Checkpoint InhibitorsNeoplasm Recurrence, LocalRadioimmunotherapyImmunotherapy

Stichwörter der Autor:innen

SCLCclinical trialsimmune checkpoint inhibitorstumor microenvironment

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
  • National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China.

ORCID-Profile: Longhui Li, Na Wang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Li, L., Liang, Y., Yu, M., Zhao, L., Mei, Q., Yu, Y., Wang, N., Zhang, D., Wang, Z., Jia, Y., & Kong, F. (2023). Advances in immune checkpoint inhibitors therapy for small cell lung cancer. Cancer Medicine, 12(10), 11097-11106. https://doi.org/10.1002/cam4.5659

Vancouver

Li L, Liang Y, Yu M, Zhao L, Mei Q, Yu Y, et al. Advances in immune checkpoint inhibitors therapy for small cell lung cancer. Cancer Medicine. 2023;12(10):11097-11106. doi:10.1002/cam4.5659

BibTeX
@article{Li2023,
  author = {Li, Longhui and Liang, Yangyueying and Yu, Minghui and Zhao, Lu and Mei, Qingyun and Yu, Yongchao and Wang, Na and Zhang, Dou and Wang, Ziwei and Jia, Yingjie and Kong, Fanming},
  title = {Advances in immune checkpoint inhibitors therapy for small cell lung cancer},
  journal = {Cancer Medicine},
  year = {2023},
  volume = {12},
  number = {10},
  pages = {11097--11106},
  doi = {10.1002/cam4.5659}
}
Kostenlos starten →